122 related articles for article (PubMed ID: 31578588)
1. Palmitoylome profiling indicates that androgens regulate the palmitoylation of α‑tubulin in prostate cancer‑derived LNCaP cells and supernatants.
Li W; Zhang J; Zou L; Cui J; Su F; Jin J; Xiao F; Liu M; Zhao G
Oncol Rep; 2019 Dec; 42(6):2788-2796. PubMed ID: 31578588
[TBL] [Abstract][Full Text] [Related]
2. [Palmitoylome profiling indicates that androgens promote the palmitoylation of metabolism-related proteins in prostate cancer-derived LNCaP cells].
Li WQ; Ren SM; Long XB; Tian YQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):227-233. PubMed ID: 32306003
[TBL] [Abstract][Full Text] [Related]
3. Androgen upregulates the palmitoylation of eIF3L in human prostate LNCaP cells.
Cui L; Liu M; Lai S; Hou H; Diao T; Zhang D; Wang M; Zhang Y; Wang J
Onco Targets Ther; 2019; 12():4451-4459. PubMed ID: 31239713
[No Abstract] [Full Text] [Related]
4. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
Pandini G; Mineo R; Frasca F; Roberts CT; Marcelli M; Vigneri R; Belfiore A
Cancer Res; 2005 Mar; 65(5):1849-57. PubMed ID: 15753383
[TBL] [Abstract][Full Text] [Related]
5. Increased Akt signaling resulting from the loss of androgen responsiveness in prostate cancer.
Dulinska-Litewka J; McCubrey JA; Laidler P
Curr Med Chem; 2013; 20(1):144-57. PubMed ID: 23033951
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor and chemokine receptors 4 and 7 form a signaling axis to regulate CXCL12-dependent cellular motility.
Hsiao JJ; Ng BH; Smits MM; Wang J; Jasavala RJ; Martinez HD; Lee J; Alston JJ; Misonou H; Trimmer JS; Wright ME
BMC Cancer; 2015 Mar; 15():204. PubMed ID: 25884570
[TBL] [Abstract][Full Text] [Related]
7. Androgen action in the prostate gland.
Yadav N; Heemers HV
Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological inhibition of the Notch pathway enhances the efficacy of androgen deprivation therapy for prostate cancer.
Cui J; Wang Y; Dong B; Qin L; Wang C; Zhou P; Wang X; Xu H; Xue W; Fang YX; Gao WQ
Int J Cancer; 2018 Aug; 143(3):645-656. PubMed ID: 29488214
[TBL] [Abstract][Full Text] [Related]
9. Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts.
Kim K; Watson PA; Lebdai S; Jebiwott S; Somma AJ; La Rosa S; Mehta D; Murray KS; Lilja H; Ulmert D; Monette S; Scherz A; Coleman JA
Clin Cancer Res; 2018 May; 24(10):2408-2416. PubMed ID: 29463549
[No Abstract] [Full Text] [Related]
10. Androgen action during prostate carcinogenesis.
Wang D; Tindall DJ
Methods Mol Biol; 2011; 776():25-44. PubMed ID: 21796518
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
12. Crosstalk Between Androgen-sensitive and Androgen-insensitive Prostate Cancer Cells.
Takezawa Y; Izumi K; Machioka K; Iwamoto H; Naito R; Makino T; Kadomoto S; Natsagdorj A; Kadono Y; Keller ET; Zhang J; Mizokami A
Anticancer Res; 2018 Apr; 38(4):2045-2055. PubMed ID: 29599322
[TBL] [Abstract][Full Text] [Related]
13. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
[TBL] [Abstract][Full Text] [Related]
14. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
[TBL] [Abstract][Full Text] [Related]
15. Androgen signal transduction and prostatic carcinoma.
Klocker H; Culig Z; Kaspar F; Hobisch A; Eberle J; Reissigl A; Bartsch G
World J Urol; 1994; 12(2):99-103. PubMed ID: 8087144
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel genes that regulate androgen receptor signaling and growth of androgen-deprived prostate cancer cells.
Levina E; Ji H; Chen M; Baig M; Oliver D; Ohouo P; Lim CU; Schools G; Carmack S; Ding Y; Broude EV; Roninson IB; Buttyan R; Shtutman M
Oncotarget; 2015 May; 6(15):13088-104. PubMed ID: 26036626
[TBL] [Abstract][Full Text] [Related]
17. Androgen ablation elicits PP1-dependence for AR stabilization and transactivation in prostate cancer.
Liu X; Han W; Gulla S; Simon NI; Gao Y; Liu J; Wang L; Yang H; Zhang X; Chen S
Prostate; 2016 May; 76(7):649-61. PubMed ID: 26847655
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of calcium/calmodulin-dependent protein kinase kinase 2 by androgen deprivation induces castration-resistant prostate cancer.
Shima T; Mizokami A; Miyagi T; Kawai K; Izumi K; Kumaki M; Ofude M; Zhang J; Keller ET; Namiki M
Prostate; 2012 Dec; 72(16):1789-801. PubMed ID: 22549914
[TBL] [Abstract][Full Text] [Related]
19. Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.
Wang Y; Liu G; Tong D; Parmar H; Hasenmayer D; Yuan W; Zhang D; Jiang J
Prostate; 2015 Aug; 75(11):1187-96. PubMed ID: 25894097
[TBL] [Abstract][Full Text] [Related]
20. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]